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ABSTRACT 
 Chemical disinfection and inactivation of viruses is largely understudied, but is very 
important especially in the case of highly infectious viruses.  The purpose of this LDRD was 
to determine the efficacy of the Sandia National Laboratories developed decontamination 
formulations against Bovine Coronavirus (BCV) as a surrogate for the coronavirus that 
causes Severe Acute Respiratory Syndrome (SARS) in humans.  The outbreak of SARS in 
late 2002 resulted from a highly infectious virus that was able to survive and remain 
infectious for extended periods.  For this study, preliminary testing with Escherichia coli 
MS-2 (MS-2) and Escherichia coli T4 (T4) bacteriophages was conducted to develop 
virucidal methodology for verifying the inactivation after treatment with the test formulations 
following AOAC germicidal methodologies. After the determination of various experimental 
parameters (i.e. exposure, concentration) of the formulations, final testing was conducted on 
BCV.  All experiments were conducted with various organic challenges (horse serum, bovine 
feces, compost) for results that more accurately represent field use condition.  The MS-2 and 
T4 were slightly more resistant than BCV and required a 2 minute exposure while BCV was 
completely inactivated after a 1 minute exposure.  These results were also consistent for the 
testing conducted in the presence of the various organic challenges indicating that the test 
formulations are highly effective for real world application. 
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INTRODUCTION 
 In general, virucidal activity and mechanism of action of various disinfectants is 
largely understudied.  Standards for virucidal testing are being developed, however none are 
mandated at this time for verifying virus inactivation.  It is largely accepted and 
recommended to follow Association of Official Analytical Chemists (AOAC) germicidal 
methods for virucidal efficacy testing (1).  The major structural targets of disinfectants 
against viruses include the viral envelope (predominantly lipid), the capsid (predominantly 
protein), and the genome (nucleic acid material) (3, 8, 9).  According to the Klein-DeForest 
Scheme, mechanism of action of various chemical disinfectants against viruses is largely due 
to the presence or absence of a viral envelope, with the latter typically being more resistant 
(3, 9).  Viruses are typically categorized into groups A (lipophilic with envelope), B 
(hydrophilic, non-enveloped), or C (intermediate solubility, nonenveloped) viruses (3, 9, 10).  
The structural target on the virus is dependent on the type of disinfectant used.  Because 
coronaviruses are an enveloped virion, they fall into the Klein-DeForest susceptibility group 
A.  Group A is susceptible to compounds including halogens, aldehydes, Quaternary 
Ammonium Compounds (QAC), phenolics, alcohols, peroxide, proteases, and detergents 
(10).  It is important to note that the susceptibility is referring to the ability of the disinfectant 
to disrupt surface properties typically important in attachment to cellular receptors, and does 
not always result in complete degradation and loss of replication functionality of the nucleic 
acid (10).   
 In this research, BCV was used as a surrogate for the virus that causes SARS to study 
inactivation.  Since there are few published protocols for determining virucidal activity of 
disinfectants, it was important to develop methodology in which exposure duration could be 
controlled by neutralizing, or quenching, the antiviral effects.  Due to the necessity of an in 
vitro cell culture for propagation of BCV, the subsequent removal of the toxicity due to the 
nature of the chemicals present in the test formulations was necessary to conduct the 
virucidal efficacy tests.  Disinfectant activity is often reduced in the presence of organic 
materials due to cross reactivity with compounds in the organic load effectiveness (4).  In 
order to be representative of environmental conditions, the test formulations were also 
challenged in the presence of organic material including horse serum (for MS-2 and T4) or 
bovine feces and compost (for BCV).   
 
MATERIALS AND METHODS 
Part I: Inactivation of Bacteriophage Viruses 
MS-2 E. coli and T4 E. coli Bacteriophage Inactivation.  Virus stock solutions 
were prepared according to the instructions from the American Type Culture Collection 
(ATCC) for both the MS-2 (ATCC 15597b) and T4 (ATCC 11303b) bacteriophages.  This 
procedure involved adding 0.5 ml of the rehydrated phage into a centrifuge tube containing 5 
ml of soft agar (Tryptic Soy Broth TSB, Difco with 0.5% agar) with a 24-hour level of 
appropriate host.  Samples were incubated as slants to allow for plaque formation.  After 
incubation period, tubes were centrifuged and supernatant was filtered through a 0.22 µm 
filter to remove the host and develop the virus stock solution.   
For the efficacy testing, 2 ml of the virus stock suspension was added to a sterile tube.  
Then 2 ml of the test formulation was added and mixed thoroughly, diluting the test 
formulation in half.  Samples were taken after 30 seconds, 1 minute, and 2 minutes by taking 
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1 ml of sample and adding to 9 ml of the previously validated neutralizer solution (data not 
shown). 
A control sample was prepared by adding 2 ml of sterile deionized water to the virus 
stock solution in place of the test formulation.  Serial dilutions were made using 0.1% 
peptone blanks.  Samples were enumerated by adding 100 µL of exposed virus to a pre-
poured Tryptic Soy Agar (TSA, Difco) plate (Figure 1).  Then approximately 5 ml of soft 
agar containing the appropriate host (E. coli 15597 for MS-2 and E. coli 11303 for T4) was 
added to sample and swirled to mix thoroughly.  Plates were incubated at 37oC for 24-48 
hours for the enumeration of plaque forming units (PFU).  The clearings or PFU’s are caused 
from the infection and ultimate lysing of the host organism due to the viable viral agent.   
  
Figure 8: Schematic of viral overlay for enumeration of plaque forming units 
Sandia National Laboratories decontamination formulations.  The various test 
decontamination formulations include Sandia’s DF-200D and the two licensee formulations: 
Modec MDF-200, and Envirofoam Technologies, Inc. EasyDecon-200.    All of these 
formulations include QAC and various concentrations of peroxide.  The formulations were 
mixed according to manufacturers’ instructions prior to use.  For proprietary reasons, the 
various components of the test formulations are noted as part A, B, and C.  The final pH of 
the various formulations is approximately 9.8.  Testing was also conducted with 5% horse 
serum as an organic challenge for testing with MS-2 and T4.   For BCV inactivation, 10% 
bovine feces or 10% compost was assessed as an organic challenge in the efficacy testing.  
 
DF-200D 
7.29 g Part A + 0.2 g Part C + 2.5 g Part B 
Modec MDF-200 
15 ml  Part A + 0.6 ml Part C + 14.4 ml Part B  
EFT Easy Decon Solution 
16.5g Penetrator (Part A) + 0.6g Booster (Part C) + 16.5 g Fortifier (Part B) 
  
Part II: BCV Inactivation 
Virus and cells.  BCV Wisconsin S1k (BCV) was propagated in Human Rectal 
Tumor 18 cells (HRT-18) with trypsin and pancreatin in the culture medium (5,6).  Inoculum 
titer was assessed using plaque assay and hemagglutinin activity (HA).  After samples were 
treated with the various decontamination formulations, samples were washed via 
ultracentrifugation.  Pellets were reconstituted in 1 ml of MEM (Minimal Essential Media) 
containing 0.2% trypsin and 0.05% pancreatin.  50 µl of this sample was used to inoculate 
HRT 18 cells for the development of cytopathic effect (CPE) indicated by syncytia.  After 
24-48 hours of incubation at 37oC with 5% CO2, samples were assessed for HA to determine 
the presence of BCV.      
Soft TSA
TSA 
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Virus Inactivation Protocol.  BCV was added to sterile 25 ml ultracentrifuge tubes 
in 1 ml aliquots.  Samples were diluted with 1 ml of MEM (for non-organic challenge) or 1 
ml of 10% bovine feces or 10% compost wt/volume in 0.01M Phosphate Buffer Solution 
(PBS) (for organic challenge).  Then, 2 ml of the test formulation was added to each tube 
using the following dilutions made with 0.01M PBS of the recommended concentration: 
50%, 25%, or 12.5%.  Samples were mixed thoroughly and exposed for either 1 or 3 minutes.  
After exposure, samples were neutralized using 4 ml neutralizer containing 50 µl 1% solution 
of Bovine Liver catalase to quench the antiviral activity and control exposure time.  Tubes 
were then brought to volume with sterile 0.01M PBS.  Samples were ultracentrifuged at 
100,000 x G force for 1 hour at 4oC.  After ultracentrifugation, supernatant was removed and 
pellet was reconstituted in 1 ml MEM containing 0.2% trypsin and 0.05% pancreatin.   
 HA for detection of BCV.  Hemagglutinin assay (HA) testing for BCV was 
conducted by the microtiter method as described elsewhere (11).  25 µl of diluent (0.1% 
bovine serum albumin in PBS) was added to each well of a V-bottom, polystyrene microtiter 
plate 1 (Dynex Technologies, Chantilly, VA).  Control and treated samples in 25 µl volumes 
were added to their respective wells.  Fresh erythrocytes from BALB/c mice were diluted to 
1% in bovine serum albumin PBS diluent, and 25 µl was added to each well.  The plates were 
incubated for 90 minutes at 4oC.  The presence of BCV antigen was indicated by the 
dispersal of erythrocytes in a lattice across the bottom of the well.  The formation of a button 
at the tip of the V-bottom well indicates the absence of BCV.  Hemagglutination titers were 
recorded as the reciprocals of the highest dilution showing complete agglutination. 
Direct fluorescent-antibody test.  To demonstrate the presence or absence of BCV, 
HRT 18 cells were infected for up to 48 hours with samples that had been treated with the 
various test formulations in 48 well microtiter plates as previously described (7).  The 
monolayers were washed with PBS (pH 7.6) and fixed with 80% acetone at 4oC for 30 to 60 
minutes.  After the monolayers were air dried, 100 µl of 8F2 labeled with fluorescent marker, 
a monoclonal antibody (MAb) that reacts with the nucleoprotein of BCV, was added to each 
well.  The plates were incubated for 30 minutes at 37oC with 5% CO2 and 95% humidity.  
After incubation, extra stain is poured off and plates were washed 2-3 times with PBS (pH 
7.6) prior to viewing with a fluorescent microscope.   
Electron microscopy of samples.  BCV was exposed to the various test formulations 
or to 0.01M PBS as a control.  Samples were prepared for electron microscopy as previously 
described by ultracentrifugation at 100,000 x G force for 1 hour at 4oC to pellet the virus 
particles (6).  The supernatant was carefully removed.  The pellet was carefully scraped and 
reconstituted in 20 drops of deionized water in a 24 well microtiter plate with 4 drops of 4% 
phosphotungstic acid and 1 drop of 0.1% bovine serum albumin.  The suspension was mixed 
carefully and nubulized onto prepared grids. 
 
RESULTS 
Part I: Inactivation of Bacteriophage Viruses  
MS-2 E. coli and T4 E. coli Bacteriophage Inactivation 
 The efficacy testing conducted with DF200D, EFT-200, and MDF-200 without 
additional organic challenge (5% horse serum) resulted in complete inactivation of both MS-
2 and T4 E. coli bacteriophages as shown in Figure 2 and 3.  The efficacy of the various test 
formulations was slightly decreased with the addition of the 5% horse serum challenge 
(figures 4 and 5) for MS-2 and T4, respectively. 
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Figure 9: MS-2 recovered after various contact with test formulations without organic challenge. 
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Figure 10: T4 recovered after various contact with test formulations without organic challenge. 
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Figure 11: MS-2 recovered after various treatments with test formulations in the presence of 5% horse 
serum. 
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Figure 12: T4 recovered after various treatments with test formulations in the presence of 5% horse 
serum. 
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Part II: BCV Inactivation 
HA for detection of BCV 
Due to the nature of the chemicals present in the test formulations and the neutralizer, 
it was necessary to include washing steps of the samples prior to inoculating the HRT 18.  
Washing with PBS followed by ultracentrifugation to pellet the virus particles was sufficient 
to remove the toxicity for cell culture (data not shown).   
 BCV titers of 5-6 log levels as demonstrated by TCID50 (neutralization titration in 
HRT 18 cells) and HA were completely inactivated after 1 and 3 minute exposure to all test 
formulations including the Sandia National Laboratories DF200D, Modec MDF-200, and 
Easy Decon-200 at 50%, 25%, and 12.5% the recommended concentration based on the 
absence of CPE in the HRT 18 cells and negative HA reaction after subsequent transfer and 
analysis.  BCV was also completely inactivated in the presence of the 10% bovine feces and 
10% compost organic challenges verified by lack of CPE in HRT 18 cells and negative HA 
results after exposure for 1 and 3 minutes to all test formulations at all test concentrations.   
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Figure 13: BCV recovered after various treatment with Sandia DF-200D, EFT-200, and MDF-200 with 
and without organic challenge (bovine feces or compost, 10%) by HA titration following infection in HRT 
18 cells. 
Direct fluorescent-antibody test  
The results of the electron microscopy visually demonstrate that the non-treated 
isolate of BCV maintained visible structural characteristics including the envelope, spike 
glycoprotein, and shorter hemagglutinin protein.  The treated samples were not visible by 
microscopy indicating the possibility that the test formulations were dissolving the viral 
envelope and potentially releasing the other structural proteins.   
 Direct fluorescent antibody (FA) was also used to demonstrate viral inactivation after 
various exposure times to the test formulations.  FA verified that BCV treated with the 
Negative HA: 
formation of button 
Positive HA: 
formation of lattice 
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various test formulations at all test concentrations (50%, 25%, and 12.5%) for 1 and 3 
minutes was completely inactivated.  This was verified by examination with a fluorescent 
microscope on the microtiter plates containing HRT 18 cells infected with the various treated 
samples and the control samples.  The HRT 18 cells infected with the control samples 
(treated with PBS in place of the test formulations) resulted in a positive FA reaction 
indicating that the BCV were intact and capable of infection.  All of the treated samples, with 
and without organic challenge, resulted in a negative FA indicating that these samples were 
inactivated resulting in loss of infectivity.   
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Figure 14: TCID50 (calculated from FA) for untreated (control) and treated samples (various 
experimental parameters.  Complete TCID50 reduction was achieved for 1 and 3 minute exposure for all 
concentrations tested and in the presence of organic challenge.  
 
Electron Microscopy of Samples 
 The results of the electron microscopy visually demonstrate that the non-treated 
isolate of BCV maintained visible structural characteristics including the envelope, spike 
glycoprotein, and shorter hemagglutinin protein.  The treated samples were not visible by 
microscopy indicating the possibility that the test formulations were dissolving the viral 
envelope and potentially releasing the other structural proteins. 
FA: apple green 
fluorescence of cyto-
plasm of HRT 18 cells 
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Figure 15: Electron Microscopy depicting intact, non-treated BCV.  Treated samples 
 
DISCUSSION 
 The purpose of these experiments was to determine the effectiveness of Sandia 
National Laboratories test decontamination formulations to inactivate SARS coronavirus by 
using a close relative, BCV that would react similarly.  Physiochemical groups of viruses (ie. 
coronaviruses) are generally recognized to react similarly to each other with regard to 
sensitivity to chemical agents (9).  The results indicate that all test formulations including 
Sandia DF-200D, Modec MDF-200, and Envirofoam Technologies, Inc. EasyDecon-200 
were all highly effect in complete BCV inactivation in contact times as low as 1 minute even 
in the presence of various organic challenges.  It is important to note that the term complete 
inactivation indicates the failure to recover the test virus, due to an inability to detect the last 
infective virus particle as defined by Chen, 1991 (3).  The loss of infectivity of the treated 
viruses is a result of the disruption of important structures on the surface (namely the viral 
receptor cites) that physically prevent successful attachment and subsequent penetration into 
the host cell (9).     
 It was important to consider the control of various testing parameters in this research 
to determine the virucidal properties of the test formulations against coronaviruses.  Because 
standard and official methods or protocols do not currently exist for testing disinfectants as 
virucides, factors including time of contact, organic load, tissue culture system, sterility, and 
temperature were all carefully controlled and monitored in this research (3, 9, 10).  In 
general, methodology for AOAC Official Method 960.09 Germicidal and Detergent 
Sanitizing Action of Disinfectants was followed and modified for specific testing using BCV 
(1).  There are different host systems used to recover viruses including tissue culture, chick 
embryo, and murine models depending on the virus being studied.  It is recommended to use 
the host system which results in the greatest level of infectivity for virucidal studies (3).  With 
BCV, tissue culture using HRT 18 cells has been previously described for enhanced 
infectivity (5).  Toxicity to the HRT 18 cells was resolved by a combination of dilution of the 
test formulation (50%, 25%, and 12.5% the recommended concentration), neutralization and 
washing/removal as recommended by Chen, 1991 (3). 
 Although the objectives in this research project did not include determining the 
mechanism of action of the various test formulation, it is likely that the lipid envelop of BCV 
is targeted and denatured by surfactant activity of the QAC and the oxidizer is acting on the 
nucleocapsid protein and possibly the genome.  In general, viruses are deemed to be 
susceptible to various disinfectants based on certain structural components, largely the 
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presence or absence of a lipid envelope.  Viruses have been classified into groups A, B, and 
C representing lipid enveloped, nonlipid non-enveloped, and nonlipid capsomeric 
lipophilicity, respectively (3, 9, 10).  Enveloped viruses have been shown to be sensitive to 
lipophilic disinfectants, including cationic QAC and other broad spectrum disinfectants (3, 4, 
9, 10).
  
Enveloped viruses, including the coronaviruses, are considered to be lipophilic and 
are soluble in lipids which allow the penetration of lipophilic antimicrobials such as QAC to 
penetrate their viral envelope typically resulting in inactivation, which was the case in this 
research.  Surprisingly, concentrations as low as 12.5% the recommended use for the test 
formulations with only a 1 minute contact time were effective in complete viral inactivation, 
even in the presence of the fecal and compost challenges.  This is probably due to synergy of 
the peroxide oxidizer present in the test formulations, even if at greatly reduced 
concentrations.  The hydroxyl radical (OH
.
) is believed to be the mechanism by which 
hydrogen peroxide effects the membrane lipids, nucleic acid materials, and proteins (2).  It is 
possible that after the QAC has penetrated the lipid envelope, the oxidizer is able to have a 
denaturing effect on the nucleocapsid protein as well as the nucleic acid material held within.  
These findings however have not been proven and would need further analysis to verify. 
  
CONCLUSION 
In conclusion, the Sandia National Laboratories test formulations used in this study 
resulted in complete viral inactivation with relatively short contact times with reduced 
concentrations and even in the presence of organic materials.  Results obtained in this study 
can be applied broadly to other lipophilic viruses within category A having a lipid envelope 
including Orthomyxoviridae (influenza) with regard to virucidal effectiveness.  Further 
analysis for category B and C viruses (nonlipid non-enveloped and nonlipid capsomeric 
lipophilicity, respectively) would need to be conducted to verify the efficacy of the Sandia 
National Laboratories test formulations against these groups. 
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